Oragenics,
Inc. (NYSE:MKT: OGEN) today announced that Dr. Martin Handfield,
Vice President of R&D for Oragenics, will be presenting a seminar
entitled “Oral Care Probiotics Development” on Tuesday, April 30th
at 5:00 pm at the SupplySide MarketPlace 2013, taking place from April
30 – May 2 at the Jacob Javits Center in New York, NY. SupplySide
MarketPlace 2013 brings together the buyers and sellers that drive the
dietary supplement, food, beverage, personal care, cosmetic and animal
nutrition marketplaces. The Oragenics seminar is part of a practical
short course entitled “Pre- & Probiotics Americas 2013: Pre- &
Probiotics - Market, Science, Regulations and Applications” and will
focus on describing the fundamental basis of oral probiotics, as well as
highlighting the competitive advantage of the Oragenics line of oral
care products.
Dr. John N. Bonfiglio, President and CEO, Oragenics, Inc., stated, “Dr
Handfield will educate the attendees on the benefits of oral probiotics
in maintaining good oral health and balance. He will outline the
advantages of the Oragenics proprietary oral probiotic blend – ProBiora3®,
which contains three strains of bacteria specifically chosen to work in
the oral cavity.”
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in novel
antibiotics against infectious disease and probiotics for oral health
for humans and pets. Oragenics has established an exclusive worldwide
channel collaboration for lantibiotics, a novel class of broad spectrum
antibiotics, with Intrexon Corporation Inc., a synthetic biology
company. The collaboration will allow Oragenics access to Intrexon's
proprietary technologies with the idea of accelerating the development
of much needed new antibiotics that will work against resistant strains
of bacteria. Oragenics also develops, markets and sells proprietary
probiotics specifically designed to enhance oral health for humans and
pets, under the brand names Evora
and ProBiora
in over 13 countries worldwide.
For more information about Oragenics, visit www.oragenics.com.
Follow Oragenics on Facebook
and Twitter.
Safe Harbor Statement: Under the Private Securities
Litigation Reform Act of 1995: This release includes forward-looking
statements that reflect the Company’s current views with respect to
future events and financial performance. These forward-looking
statements are based on management’s beliefs and assumptions and
information currently available. The words “believe,” “expect,”
“anticipate,” “intend,” “estimate,” “project” and similar expressions
that do not relate solely to historical matters identify forward-looking
statements. Investors should be cautious in relying on forward-looking
statements because they are subject to a variety of risks,
uncertainties, and other factors that could cause actual results to
differ materially from those expressed in any such forward-looking
statements. These factors include, but are not limited to our ability to
raise additional capital to sustain our operations beyond March 31, 2014
and those set forth in our most recently filed annual report on Form
10-K and quarterly report on Form 10-Q, and other factors detailed from
time to time in filings with the U.S. Securities and Exchange
Commission. We expressly disclaim any responsibility to update
forward-looking statements.
